Phaseline

Targets › TGF-BETA

TGF-BETA: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on TGF-BETA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyPirfenidone
Anti-fibrotic agent with anti-inflammatory properties
TNF, TGF-BETAPhase 2To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal CarcinomaDec 2026

Conditions

To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma (1)

Modalities

mixed (1)

Companies

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)

Related targets

TNF (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.